Do you want to read an article? Please log in or register.
Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer
Genitourinary Cancer
Related content
RECOMMENDED
Breast Cancer
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Cancer Treat Rev
Nakatani S, Hayashi T, Yamamoto K, Maeda H
doi: 10.1016/j.ctrv.2025.102923
Genitourinary Cancer
Focal therapy using high-intensity focused ultrasound with intraoperative prostate compression for patients with localized prostate cancer: a multi-center prospective study with 7 year experience
Prostate Cancer Prostatic Dis
Shoji S, Naruse J, Ohno S, Aoki M, Takahashi K, Yuzuriha S, Kuroda S, Umemoto T, Nakajima N, Hasegawa M, Kawamura Y, Kajiwara H, Hashida K, Uemura K, Hasebe T, Tajiri T
doi: 10.1038/s41391-024-00921-0
Breast Cancer
Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting
Int J Cancer
Liu B, Song Y, Xu Y, Sun Q, Zhou Y, Lin Y
doi: 10.1002/ijc.35140
Gastrointestinal Cancer
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial
Ann Oncol
Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Boilève A, Delaye M, Gourgou S, Pezzella V, Borg C
doi: 10.1016/j.annonc.2024.06.019
Genitourinary Cancer
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer
J Clin Oncol
Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza D, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Rodgers JP, Sandler HM
doi: 10.1200/JCO.23.02445
Genitourinary Cancer
Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience
Prostate
Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H
doi: 10.1002/pros.24880
Gastrointestinal Cancer
Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis
J Clin Oncol
Sayan M, Chen MH, Loffredo M, McMahon E, Moningi S, Orio PF, Nguyen PL, D'Amico AV
doi: 10.1200/JCO.23.02394
Lung, Respiratory and Thoracic Cancer
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study
Lung Cancer
Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H
doi: 10.1016/j.lungcan.2024.108056
SPECIAL REPORT
Genitourinary Cancer